Treace Medical Concepts (TMCI) Short term Debt (2020 - 2026)

Treace Medical Concepts (TMCI) posted Short term Debt of $1.8 million for Q1 2026, up 1.78% on a QoQ basis from $1.7 million in Q4 2025, and up 3846.67% year-over-year from $45000.0 in Q1 2025.

Treace Medical Concepts (TMCI) Short term Debt (2020 - 2026) Analysis & Trends

Treace Medical Concepts' Short term Debt history runs 3 years deep, the most recent figure standing at $1.8 million for Q1 2026.

  • Quarterly Short term Debt rose 3846.67% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (up 3846.67% YoY) and the FY2025 annual result came in at $1.7 million, changed N/A from the prior year.
  • Short term Debt was $1.8 million for Q1 2026 at Treace Medical Concepts, up from $1.7 million in the prior quarter.
  • Across five years, Short term Debt topped out at $1.8 million in Q3 2025 and bottomed at $45000.0 in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn
9 Smith & Nephew 25.80 Bn 25.22 Bn -
10 Treace Medical Concepts 261.60 Mn 209.75 Mn 37.41 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.78 Mn
Dec 31, 2025 1.75 Mn
Sep 30, 2025 1.80 Mn
Jun 30, 2025 1.11 Mn
Mar 31, 2025 45,000.00
Dec 31, 2020 1.79 Mn